AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9856652 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion 5-fluorouracil (5FU)
Number of subjects: 87
Study 9856652 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion 5-fluorouracil with paclitaxel
Number of subjects: 87
Study 8602900 — intervention group
Group type: EXPERIMENTAL
Intervention: Listerine
Number of subjects: 30
Study 8602900 — intervention group
Group type: EXPERIMENTAL
Intervention: Scope
Number of subjects: 30
Study 8602900 — intervention group
Group type: EXPERIMENTAL
Intervention: Rembrandt Mouth Refreshing Rinse
Number of subjects: 30
Study 8602900 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear Choice
Number of subjects: 30
Study 8602900 — intervention group
Group type: COMPARATOR
Intervention: Water Control
Number of subjects: 30
Study 2691808 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg Quazepam (QZP) for 8 weeks
Number of subjects: 65
Study 2691808 — intervention group
Group type: COMPARATOR
Intervention: Triazolam (TRZ) for 8 weeks
Number of subjects: 65
Study 603221 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol (0.2 mg/kg body weight) with atropine (0.01 mg/kg body weight)
Number of subjects: 39
Study 31809985 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 (oral Omega-3 2 g twice daily)
Number of subjects: 53
Study 31292183 — intervention group
Group type: COMPARATOR
Intervention: 0 mg thiamine (control)
Number of subjects: 320
Study 31292183 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 mg thiamine
Number of subjects: 320
Study 31292183 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4 mg thiamine
Number of subjects: 320
Study 31292183 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg thiamine
Number of subjects: 320
Study 28167007 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinuclean Nebules treatment administered by nasal douche (Rinowash) twice/day for 10 days
Number of subjects: 61
Study 28167007 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline administered by nasal douche (Rinowash) twice/day for 10 days
Number of subjects: 61
Study 25819209 — intervention group
Group type: EXPERIMENTAL
Intervention: Sharp needle
Number of subjects: 35
Study 25819209 — intervention group
Group type: COMPARATOR
Intervention: Blunt needle
Number of subjects: 35
Study 24032636 — intervention group
Group type: EXPERIMENTAL
Intervention: Diprifusor (ke0 0.26 min‐1)
Number of subjects: 60
Study 24032636 — intervention group
Group type: COMPARATOR
Intervention: Base Primea (ke0 1.21 min‐1)
Number of subjects: 60
Study 21804625 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel™
Number of subjects: 204
Study 21804625 — intervention group
Group type: COMPARATOR
Intervention: AuraOnce™
Number of subjects: 204
Study 18543100 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Number of subjects: 167
Study 18543100 — intervention group
Group type: EXPERIMENTAL
Intervention: Results sharing process
Number of subjects: 167
Study 18543100 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with results sharing
Number of subjects: 167
Study 18543100 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety after results sharing
Number of subjects: 167
Study 16440357 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive lamivudine therapy (100 mg daily from the start of TACL)
Number of subjects: 73
Study 16440357 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lamivudine therapy)
Number of subjects: 73
Study 15214970 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurosurgical procedures
Number of subjects: 68
Study 11761792 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality improvement model using academic detailing and electronic medical records (EMRs)
Number of subjects: 23
Study 11761792 — intervention group
Group type: COMPARATOR
Intervention: Control practices receiving copies of clinical practice guidelines and quarterly updates
Number of subjects: 23
Study 11761792 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention practices receiving similar information and participating in regular site visits and investigator meetings
Number of subjects: 23
Study 9132982 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole vaginal tablets (2 x 100 mg once a day for 7 days)
Number of subjects: 168
Study 9132982 — intervention group
Group type: EXPERIMENTAL
Intervention: AVC suppositories (1.05 g sulfanilamide, 14 mg aminacrine hydrochloride, 140 mg allantoin twice a day for 7 days)
Number of subjects: 168
Study 9132982 — intervention group
Group type: COMPARATOR
Intervention: Oral metronidazole (2 g as a single oral dose)
Number of subjects: 168
Study 8421182 — intervention group
Group type: EXPERIMENTAL
Intervention: Endotoxin (2 ng/kg of body weight)
Number of subjects: 0
Study 8421182 — intervention group
Group type: EXPERIMENTAL
Intervention: Tumor necrosis factor-alpha (50 micrograms/m2)
Number of subjects: 0
Study 3721054 — intervention group
Group type: EXPERIMENTAL
Intervention: RV11 (propionyl erythromycin mercaptosuccinate) 500 mg oral dose
Number of subjects: 0
Study 31762222 — intervention group
Group type: EXPERIMENTAL
Intervention: PHILOS combined with fibular allograft
Number of subjects: 42
Study 31762222 — intervention group
Group type: COMPARATOR
Intervention: PHILOS alone
Number of subjects: 42
Study 29962591 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.075 mg i.v.
Number of subjects: 90
Study 29962591 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 8 mg i.v.
Number of subjects: 90
Study 29962591 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron 0.075 mg and Dexamethasone 4 mg i.v.
Number of subjects: 90
Study 26902549 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated admission shock index (n=321)
Number of subjects: 791
Study 26902549 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission shock index
Number of subjects: 791
Study 24989060 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg/day
Number of subjects: 428
Study 24989060 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine 20-120 mg/day
Number of subjects: 428
Study 24989060 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (various doses)
Number of subjects: 428
Study 22393128 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX and prednisone (10 mg/d)
Number of subjects: 236
Study 22393128 — intervention group
Group type: COMPARATOR
Intervention: MTX and placebo
Number of subjects: 236
Study 20141566 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose atorvastatin
Number of subjects: 0
Study 20141566 — intervention group
Group type: COMPARATOR
Intervention: Usual dose of simvastatin
Number of subjects: 0
Study 17932844 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5% sodium hyaluronate (BD Multivisc)
Number of subjects: 30
Study 17932844 — intervention group
Group type: COMPARATOR
Intervention: Soft shell technique (Biolon and Viscoat)
Number of subjects: 30
Study 16127109 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital in the Home (HITH) treatment
Number of subjects: 100
Study 16127109 — intervention group
Group type: COMPARATOR
Intervention: Hospital treatment
Number of subjects: 100
Study 12789224 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 0.25 mg/kg orally twice daily for 1 week
Number of subjects: 0
Study 12789224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10229311 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin: 0.1 IU/kg body weight/day of neutral protamine hagedorn (NPH) insulin once a day
Number of subjects: 10
Study 10229311 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 10
Study 10229311 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin
Number of subjects: 10
Study 8553397 — intervention group
Group type: EXPERIMENTAL
Intervention: Stroke unit rehabilitation practice
Number of subjects: 0
Study 1859050 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone plus azathioprine (n = 14)
Number of subjects: 27
Study 1859050 — intervention group
Group type: COMPARATOR
Intervention: Prednisone plus placebo (n = 13)
Number of subjects: 27
Study 1859050 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone plus azathioprine
Number of subjects: 27
Study 1859050 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone plus azathioprine (adjusted for age)
Number of subjects: 27
Study 6574528 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone administered at 1900h
Number of subjects: 6
Study 6574528 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone administered at 2300h
Number of subjects: 6
Study 4028724 — intervention group
Group type: EXPERIMENTAL
Intervention: MLCu 250
Number of subjects: 549
Study 4028724 — intervention group
Group type: EXPERIMENTAL
Intervention: MLCu 375
Number of subjects: 549
Study 4028724 — intervention group
Group type: COMPARATOR
Intervention: MLCu 250 and MLCu 375
Number of subjects: 549
Study 30371190 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab
Number of subjects: 4983
Study 30371190 — intervention group
Group type: COMPARATOR
Intervention: Placebo/Ezetimibe
Number of subjects: 4983
Study 26654211 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy (CT) for recurrent MDD, 12-14 weeks duration
Number of subjects: 523
Study 26654211 — intervention group
Group type: COMPARATOR
Intervention: Continuation-phase CT or clinical management plus double-blind fluoxetine or pill placebo for higher risk patients (n = 241, 83%)
Number of subjects: 523
Study 26654211 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuation-phase therapy
Number of subjects: 523
Study 26654211 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower and higher risk groups
Number of subjects: 523
Study 24637345 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention condition (alternating between seated and standing work posture every 30 min)
Number of subjects: 23
Study 24637345 — intervention group
Group type: COMPARATOR
Intervention: Control condition (seated work posture)
Number of subjects: 23
Study 23357715 — intervention group
Group type: EXPERIMENTAL
Intervention: Gluten-containing diet (GCD)
Number of subjects: 45
Study 23357715 — intervention group
Group type: COMPARATOR
Intervention: Gluten-free diet (GFD)
Number of subjects: 45
Study 20856584 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel filtration device
Number of subjects: 240
Study 20856584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 19106471 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mm of gutta‐percha retained
Number of subjects: 126
Study 19106471 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mm of gutta‐percha retained
Number of subjects: 126
Study 19106471 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mm of gutta‐percha retained
Number of subjects: 126
Study 19106471 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 mm positive control)
Number of subjects: 126
Study 19106471 — intervention group
Group type: COMPARATOR
Intervention: Control group (5 mm negative control)
Number of subjects: 126
Study 16607678 — intervention group
Group type: EXPERIMENTAL
Intervention: Splenectomy during total gastrectomy (104 patients)
Number of subjects: 207
Study 16607678 — intervention group
Group type: COMPARATOR
Intervention: Total gastrectomy without splenectomy (103 patients)
Number of subjects: 207
Study 11579985 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction (listening to an audiotape) during the first hour of exposure treatment
Number of subjects: 60
Study 11579985 — intervention group
Group type: COMPARATOR
Intervention: Exposure without distraction during the first hour of exposure treatment
Number of subjects: 60
Study 9539197 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingent group (watching VCR movies and playing video games contingent upon riding the bicycle)
Number of subjects: 14
Study 9539197 — intervention group
Group type: COMPARATOR
Intervention: Control group (all physical and sedentary activities freely available)
Number of subjects: 14
Study 7742260 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 360 mg/day
Number of subjects: 2
Study 7742260 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2
Study 2646252 — intervention group
Group type: EXPERIMENTAL
Intervention: Destagnation (radiation plus Destagnation)
Number of subjects: 188
Study 2646252 — intervention group
Group type: COMPARATOR
Intervention: Control (radiation only)
Number of subjects: 188
Study 1101614 — intervention group
Group type: EXPERIMENTAL
Intervention: etidocaine 1% with adrenaline (5 mug/ml)
Number of subjects: 40
Study 1101614 — intervention group
Group type: COMPARATOR
Intervention: bupivacaine 0.5% with adrenaline (5 mug/ml)
Number of subjects: 40
Study 29615751 — intervention group
Group type: EXPERIMENTAL
Intervention: InSAR analysis using data from Envisat, ALOS‐1, TerraSAR‐X, and Sentinel‐1
Number of subjects: 68
Study 29615751 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal component analysis (PCA) on 200 randomly selected time series of the LUC
Number of subjects: 68
Study 29615751 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydro‐thermal model using InSAR scores from PCA
Number of subjects: 68
Study 27175810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cordless Sonicision™ (Covidien, Mansfield, MA)
Number of subjects: 30
Study 27175810 — intervention group
Group type: COMPARATOR
Intervention: Wired HARMONIC ACE®+ (Ethicon Endo‐Surgery Inc., Cincinnati, OH)
Number of subjects: 30
Study 24460796 — intervention group
Group type: EXPERIMENTAL
Intervention: ER-treated injuries
Number of subjects: 4819
Study 24460796 — intervention group
Group type: COMPARATOR
Intervention: Non-ER treated injuries
Number of subjects: 4819
Study 24460796 — intervention group
Group type: COMPARATOR
Intervention: Not treated injuries
Number of subjects: 4819
Study 24460796 — intervention group
Group type: EXPERIMENTAL
Intervention: Aged 18 to 30 years (ER-treated)
Number of subjects: 4819
Study 24460796 — intervention group
Group type: EXPERIMENTAL
Intervention: Blacks (ER-treated)
Number of subjects: 4819
Study 24460796 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanics (ER-treated)
Number of subjects: 4819
Study 24460796 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive RAPS4 (ER-treated)
Number of subjects: 4819
Study 24460796 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor vehicle injuries (ER-treated)
Number of subjects: 4819
Study 24460796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting/piercing injuries (ER-treated)
Number of subjects: 4819
Study 24460796 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive RAPS4 (general population)
Number of subjects: 4819
Study 24460796 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor vehicle injuries (general population)
Number of subjects: 4819
Study 24460796 — intervention group
Group type: EXPERIMENTAL
Intervention: Cutting/piercing injuries (general population)
Number of subjects: 4819
Study 24460796 — intervention group
Group type: EXPERIMENTAL
Intervention: Blacks (general population)
Number of subjects: 4819
Study 24460796 — intervention group
Group type: EXPERIMENTAL
Intervention: Hispanics (general population)
Number of subjects: 4819
Study 22587850 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi once a week (TC1)
Number of subjects: 684
Study 22587850 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai chi twice a week (TC2)
Number of subjects: 684
Study 22587850 — intervention group
Group type: COMPARATOR
Intervention: Low-level exercise program (LLE)
Number of subjects: 684
Study 22587850 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (TC1, TC2, LLE)
Number of subjects: 684
Study 20617220 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional loading protocol
Number of subjects: 106
Study 20617220 — intervention group
Group type: EXPERIMENTAL
Intervention: Early loading protocol
Number of subjects: 106
Study 20617220 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week loading protocol
Number of subjects: 106
Study 20617220 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week loading protocol
Number of subjects: 106
Study 20617220 — intervention group
Group type: EXPERIMENTAL
Intervention: Roughened implant surfaces
Number of subjects: 106
Study 20617220 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment systems
Number of subjects: 106
Study 20617220 — intervention group
Group type: COMPARATOR
Intervention: Overall success rate
Number of subjects: 106
Study 18349537 — intervention group
Group type: EXPERIMENTAL
Intervention: MRA
Number of subjects: 97
Study 18349537 — intervention group
Group type: EXPERIMENTAL
Intervention: TCD
Number of subjects: 97
Study 18349537 — intervention group
Group type: COMPARATOR
Intervention: iaDSA
Number of subjects: 97
Study 15995958 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART)
Number of subjects: 192
Study 15995958 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 192
Study 12606165 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg Cu/l solution
Number of subjects: 30
Study 12606165 — intervention group
Group type: COMPARATOR
Intervention: <0.01 mg Cu/l solution (control)
Number of subjects: 30
Study 10194774 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative image analysis technique for the assessment of axonal injury using beta-amyloid precursor protein immunocytochemistry.
Number of subjects: 15
Study 10194774 — intervention group
Group type: COMPARATOR
Intervention: Semi-quantitative grading systems for determining the relationship between the extent of DAI and clinical features.
Number of subjects: 15
Study 7755076 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous saline solution containing a multivitamin preparation
Number of subjects: 20
Study 7755076 — intervention group
Group type: COMPARATOR
Intervention: Matched controls (nonvomiting pregnant women)
Number of subjects: 20
Study 7755076 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with longer duration of vomiting
Number of subjects: 20
Study 7755076 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment regimen
Number of subjects: 20
Study 2159860 — intervention group
Group type: EXPERIMENTAL
Intervention: 360 mg gamma-linolenic acid
Number of subjects: 22
Study 2159860 — intervention group
Group type: COMPARATOR
Intervention: Indistinguishable placebo capsules
Number of subjects: 22
Study 339932 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg and 100 mg)
Number of subjects: 10
Study 339932 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol (80 mg)
Number of subjects: 10
Study 31699211 — intervention group
Group type: COMPARATOR
Intervention: Varenicline tartrate (reference)
Number of subjects: 30
Study 31699211 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline oxalate (test)
Number of subjects: 30
Study 29198872 — intervention group
Group type: EXPERIMENTAL
Intervention: ACB single injection with IV Dex 8 mg
Number of subjects: 177
Study 29198872 — intervention group
Group type: EXPERIMENTAL
Intervention: ACB single injection without IV Dex
Number of subjects: 177
Study 29198872 — intervention group
Group type: COMPARATOR
Intervention: ACB catheter technique
Number of subjects: 177
Study 29198872 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 177
Study 27225334 — intervention group
Group type: EXPERIMENTAL
Intervention: Omarigliptin
Number of subjects: 0
Study 24720686 — intervention group
Group type: EXPERIMENTAL
Intervention: Prevention Practitioner (PP) intervention
Number of subjects: 0
Study 22800401 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab treatment for 6 months
Number of subjects: 14
Study 20573236 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Links Nurturing Programme (FLNP)
Number of subjects: 288
Study 20573236 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 288
Study 17587389 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg)
Number of subjects: 41
Study 17587389 — intervention group
Group type: COMPARATOR
Intervention: Quinapril (20 mg)
Number of subjects: 41
Study 16095548 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid injections (ESIs) with local anaesthetic
Number of subjects: 228
Study 16095548 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline injection)
Number of subjects: 228
Study 16095548 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural steroid injections (ESIs)
Number of subjects: 228
Study 16095548 — intervention group
Group type: EXPERIMENTAL
Intervention: One ESI
Number of subjects: 228
Study 12189359 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir 1250 mg twice a day plus low doses of ritonavir (100 mg)
Number of subjects: 24
Study 12189359 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir 1250 mg twice a day plus low doses of ritonavir (200 mg)
Number of subjects: 24
Study 10484575 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg loratadine
Number of subjects: 25
Study 10484575 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 7547368 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy withdrawal
Number of subjects: 112
Study 7547368 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy with anticoagulant therapy
Number of subjects: 112
Study 1953230 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone plus azathioprine
Number of subjects: 28
Study 1953230 — intervention group
Group type: COMPARATOR
Intervention: Continuation of various conventional antirheumatic drugs
Number of subjects: 28
Study 7284971 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-dose (4000 rads) radiation + 5-fluorouracil (5-FU)
Number of subjects: 194
Study 7284971 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (6000 rads) radiation + 5-fluorouracil (5-FU)
Number of subjects: 194
Study 7284971 — intervention group
Group type: COMPARATOR
Intervention: High-dose (6000 rads) radiation alone
Number of subjects: 194
Study 30740695 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) oral solution (Epidiolex; 100 mg/mL), titrated from 2.5 to 20 mg/kg/d over a 2-week titration period, with a mean modal dose of 23 mg/kg/d after a median treatment duration of 38 weeks.
Number of subjects: 366
Study 28523476 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Navigator Program (PN)
Number of subjects: 1911
Study 28523476 — intervention group
Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 1911
Study 27085323 — intervention group
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel (nab-P) 125 mg/m² + Gemcitabine (Gem) 1000 mg/m²
Number of subjects: 861